New Haven-based biotech Rallybio, founded by three former Alexion executives, pulled in nearly $93 million in its recent IPO.
Rallybio is developing drugs for the treatment of rare and severe diseases in the areas of hematology, immuno-inflammation, maternal fetal health and metabolic disorders.